Siren, L.L.C. Bei Gene, Ltd. Transaction History

Siren, L.L.C.

$2 Trillion
Q3 2024

A detailed history of Siren, L.L.C. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Siren, L.L.C. holds 563,314 shares of BGNE stock, worth $107 Million. This represents 6.32% of its overall portfolio holdings.

Number of Shares

563,314

Holding current value

$107 Million

% of portfolio

6.32%

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 13, 2024	BUY	$143.93 - $224.51 $81.1 Million - $126 Million	563,314 New	563,314 $126 Billion

Others Institutions Holding BGNE

# of Institutions

250

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$2.01 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.23 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$986 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$948 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$706 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Siren, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Siren, L.L.C. with notifications on news.

Account